Nurix Therapeutics 

Quarterly Financials

Values in thousands 2024-08-31 2024-05-31 2024-02-29 2023-11-30
Revenue
$12,588
$12,092
$16,585
$15,159
Gross Profit
8,442
8,001
12,697
11,402
EBITDA
-50,465
-44,449
-41,331
-41,577
EBIT
-54,611
-48,540
-45,219
-45,334
Net Income
-48,956
-44,546
-41,518
-41,956
Net Change In Cash
12,588
12,092
16,585
15,159
Free Cash Flow
-44,524
-41,642
-44,835
19,164
Cash
99,044
116,790
49,813
54,627
Basic Shares
72,779
62,377
54,903
54,670

Annual Financials

Values in thousands 2023-11-30 2022-11-30 2021-11-30 2020-11-30
Revenue
$76,987
$38,627
$29,750
$17,820
Gross Profit
-112,161
38,627
29,750
17,820
EBITDA
-141,409
-173,059
-111,804
-62,803
EBIT
-155,063
-183,867
-117,886
-64,983
Net Income
-143,948
-166,045
-117,194
-43,242
Net Change In Cash
76,987
38,627
29,750
17,820
Cost of Revenue
-15,417
-38,734
84,540
Free Cash Flow
-89,766
-172,051
-90,026
-4,633
Cash
54,627
64,474
80,506
119,356
Basic Shares
54,337
48,607
42,895
15,673

Earnings Calls

Quarter EPS
2024-08-31
-$0.67
2024-05-31
-$0.71
2024-02-29
-$0.76
2023-11-30
-$0.77